Egyptian pharmaceutical company Nile Pharma has reported a significant increase in its net profit for the 2025/2026 fiscal year. According to the company's financial statements, Nile Pharma achieved a net profit after tax of 256.37 million Egyptian pounds for the year ending June 30, 2026. This represents a substantial increase of 103.9% compared to 125.73 million pounds in the previous fiscal year.
The company's revenues also experienced a notable growth, rising to 2.134 billion pounds in the 2025/2026 fiscal year, up from 1.290 billion pounds in the previous year. This marks a growth of 65.5%. The gross profit of Nile Pharma increased to 676.08 million pounds, compared to 407.81 million pounds in the same period last year, representing a growth of 65.8%.
The company's financial performance was also reflected in its gross profit margin, which remained relatively stable at 31.7% compared to 31.6% in the previous fiscal year. Nile Pharma's pre-tax profit was 312.36 million pounds, up from 163.23 million pounds in the 2024/2025 fiscal year, representing a growth of 91.4%.
In terms of its financial position, Nile Pharma's net working capital increased to 112.61 million pounds as of June 30, 2026, compared to a negative 28.76 million pounds in the previous fiscal year. The company's equity also grew to 1.071 billion pounds, up from 743.29 million pounds, representing a growth of 44.1%.
The company's capital and reserves also experienced significant growth, with its paid-up capital increasing to 500 million pounds, up from 300 million pounds, representing a growth of 66.7%. The company's reserves stood at 236.23 million pounds as of June 30, 2026, compared to 218.5 million pounds in the previous fiscal year.
Nile Pharma's cash flow statement revealed that the company experienced negative cash flows from operating activities of 292.77 million pounds in the 2025/2026 fiscal year, compared to positive cash flows of 934 thousand pounds in the previous year. The company's cash flows used in investing activities were 258.45 million pounds, down from 437.36 million pounds in the same period last year.
On September 21, 2026, Nile Pharma's board of directors approved the company's financial statements for the 2025/2026 fiscal year, which showed a net profit of 312.4 million pounds, up from 163.2 million pounds in the previous year. The board also proposed the distribution of 189.1 million pounds in the form of free shares to shareholders, at a rate of 0.37 free shares per share.
Key points
- Nile Pharma's net profit surged 103.9% to 256.37 million Egyptian pounds in the 2025/2026 fiscal year.
- The company's revenues grew 65.5% to 2.134 billion pounds in the 2025/2026 fiscal year.
- Nile Pharma's board proposed the distribution of 189.1 million pounds in free shares to shareholders.
